Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia
BMC Neuroscience March 5, 2015 Ludmyla Kandratavicius, Priscila Alves Balista, Daniele C. Wolf et al. 40 citations
BACKGROUND: Better treatments for schizophrenia are urgently needed. The therapeutic use of the nitric oxide (NO)-donor sodium nitroprusside (SNP) in patients with schizophrenia has shown promising results. The role of NO in schizophrenia is still unclear, and NO modulation is unexplored in ketamine (KET) animal models to date. In the present study, we compared the behavioral effects of pre-...